NovaBridge Biosciences
NBP$173M
Micro CapNASDAQPharmaceutical Preparations🇺🇸North AmericaROCKVILLE32 employees
Drugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
2
Next Catalyst
Jun 25, 2026
4dMarket Overview
Stock performance and key metrics
NBP News
Catalyst Timeline
2 upcoming, 0 past
EarningsNext
NBP Earnings Report
Jun 25, 2026Confirmed
EPS Est: $-0.12 | FQ end 2026-03
1 more catalyst beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
Drug Pipeline
Liquid 13-Cis Retinoic Acid
Neuroblastoma
Oral Hydroxyurea (100 mg/mL) Solution
Sickle Cell Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Liquid 13-Cis Retinoic Acid | Phase 2 | Neuroblastoma | - | - |
Oral Hydroxyurea (100 mg/mL) Solution | Phase 2 | Sickle Cell Disease | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply